Class summary at a glance.

Every drug in the Programmed Death Receptor-1 Blocking Antibody class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 10tracked in Part D
CY24 Part D spend: $346.9Mcombined across class
Total Rx claims: 29K6K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Pembrolizumab

Brand: KEYTRUDA · 19K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2015-01-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $228.4M

Class share

66%

of class CY24 spend

View profile →

Nivolumab

Brand: OPDIVO · 7K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2014-12-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $80.7M

Class share

23%

of class CY24 spend

View profile →

Atezolizumab

Brand: TECENTRIQ · 3K Part D claims (CY24) · 718 beneficiaries · First FDA approval: 2016-05-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $37.8M

Class share

11%

of class CY24 spend

View profile →

Atezolizumab and Hyaluronidase-Tqjs

Brand: Tecentriq Hybreza · — Part D claims (CY24) · First FDA approval: 2024-09-12

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Dostarlimab

Brand: Jemperli · — Part D claims (CY24) · First FDA approval: 2021-04-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nivolumab and Hyaluronidase-Nvhy

Brand: OPDIVO QVANTIG · — Part D claims (CY24) · First FDA approval: 2024-12-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nivolumab and Relatlimab-Rmbw

Brand: OPDUALAG · — Part D claims (CY24) · First FDA approval: 2022-03-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Retifanlimab-Dlwr

Brand: ZYNYZ · — Part D claims (CY24) · First FDA approval: 2023-03-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Tislelizumab-Jsgr

Brand: TEVIMBRA · — Part D claims (CY24) · First FDA approval: 2024-03-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Toripalimab-Tpzi

Brand: LOQTORZI · — Part D claims (CY24) · First FDA approval: 2023-10-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.